Prostate Cancer ADT Increases Bone Fracture Risk
Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.
Diagnosis & Disease Information
In Advanced Prostate Cancer, Statin Use With Androgen Ablation Ups Survival
Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.
Greater PSA Decline Predicts Better 177Lu-PSMA-617 Outcomes in mCRPC
Latest findings are from a post hoc analysis of the phase 3 VISION trial.
Olaparib + Abiraterone Gets Priority Review for Castration-Resistant Prostate Cancer
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Darolutamide Plus Docetaxel Gets Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
Camcevi Now Available for Advanced Prostate Cancer Treatment
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
